IMMUNOCONJUGATES, METHOD OF PREPARING IMMUNOCONJUGATE, PHARMACEUTICAL COMPOSITION, USE OF IMMUNOCONJUGATE

FIELD: chemistry of protein. SUBSTANCE: invention relates to new hybrid proteins that consists of tumor-associated member directed against cell-target, preferably, monoclonal antibody or its fragment that recognizes the molecule expressing mainly on human tumor cells, for example, such as receptor o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ILKA FON KHEGEN, VOL'FGANG SHTRITTMATTER, ZIGFRID MATTSKU, JORG SHTADL'MJULLER, UVE KHOFMANN, KARLOTA-SIL'VIJA EGGLE
Format:	Patent
Sprache:	eng ; rus
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES USING MICROORGANISMS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	FIELD: chemistry of protein. SUBSTANCE: invention relates to new hybrid proteins that consists of tumor-associated member directed against cell-target, preferably, monoclonal antibody or its fragment that recognizes the molecule expressing mainly on human tumor cells, for example, such as receptor of epidermal growth factor; and from biologically active ligand, for example, such as growth factor and/or differentiation factor. Obtained hybrid protein can be used for biologically active ligand delivery to specific cells or tissue-target. New immunoconjugates can be used for tumor disease treatment. EFFECT: enhanced effectiveness of immunoconjugates. Изобретение относится к новым гибридным белкам, которые состоят из опухолеассоциированного и направленного против клетки-мишени элемента, предпочтительно моноклинального антитела или его фрагмента, распознающего молекулу, экспрессирующуюся преимущественно на опухолевых клетках человека, например такую, как рецептор эпидермального фактора роста (EGFR); и из биологически активного лиганда, например такого, как фактор роста и/или фактор дифференцировки. Полученный гибридный белок может быть использован для доставки биологически активного лиганда к специфическим клеткам или тканям-мишеням. Новые иммуноконъюгаты могут быть использованы для лечения опухолевых заболеваний.